Translational Research in ROS1-Positive NSCLC: Are We Moving Out of the Six Blind Men and the Elephant Stage?

Authors :: Lee JB
Nagasaka M
Source :: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2024 Apr; Vol. 19 (4), pp. 525-527.
Publication Year :: 2024
Abstract: Competing Interests: Disclosure Dr. Lee reports receiving research grants from Yuhan. Dr. Nagasaka reports receiving consulting fees from Caris Life Sciences; payment or honoraria for lectures, presentations, speaker’s bureaus, manuscript writing, or educational events from AstraZeneca, Daiichi Sankyo, Novartis, EMD Serono, Pfizer, Eli Lilly, Regeneron, Genentech, Takeda, Janssen, Mirati, Blueprint Medicine, and Bristol-Myers Squibb; and support for attending meetings and/or travel from AnHeart Therapeutics.

Subjects :: Humans
Protein-Tyrosine Kinases genetics
Translational Research, Biomedical
Proto-Oncogene Proteins
Protein Kinase Inhibitors
Lung Neoplasms genetics
Carcinoma, Non-Small-Cell Lung genetics

Language :: English
ISSN :: 1556-1380
Volume :: 19
Issue :: 4
Database :: MEDLINE
Journal :: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Publication Type :: Editorial & Opinion
Accession number :: 38582542
Full Text :: https://doi.org/10.1016/j.jtho.2024.01.009

Full Text Access

Tools